Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P080006/S193

Attain Ability Lead (4196, 4296), Attain Ability Lead (4396), Attain Performa Lead (4298, 4398, 4598), Attain Stability

Medtronic, Inc. · Decision date Jun 24, 2026

FDA DECISIONP080006/S193

What did the FDA decide?

FDA records P080006/S193 as a supplement to PMA P080006, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jun 24, 2026.

FDA approval order statement

reduced stability testing intervals for various cardiac lead families containing Dexamethasone or Beclomethasone Dipropionate
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Jun 24, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P080006/S193
Regulatory pathway
PMA supplement
Product code
OJX
Decision code
OK30
Decision date
Jun 24, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Drug eluting permanent left ventricular (lv) pacemaker electrode.

Product code
OJX
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P080006/S192 · Related supplement

    Attain Ability Lead, Attain Performa Lead (4398,4598), Attain Performa Lead (4298), Attain Stability Quad MRI Lead

  2. P080006/S193 received

    Application receipt date recorded by FDA.

  3. P080006/S193 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P080006. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P080006

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA supplementApr 15, 2026FDA

Explore the linked device profile

Other records with product code OJX

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA supplementFeb 10, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
710 Medtronic Pkwy. NE, Minneapolis, MN, 55432

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records